Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Buse.
Statin treatment in diabetes mellitus.
Clin Diab, 21 (2003), pp. 168-171
[2.]
J.M. McKenney.
Potential nontraditional applications of statins.
Ann Pharmacother, 37 (2003), pp. 1063-1071
[3.]
M. Laakso.
Dyslipidemia, morbidity, and mortality in non-insulindependents diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus.
J Diab Compl, 11 (1997), pp. 137-141
[4.]
Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).
JAMA, 285 (2001), pp. 2486-2497
[5.]
American diabetes association. standards of medical care in diabetes.
Diabetes Care, 27 (2004), pp. S15-S35
[6.]
M. Brandle, M.B. Davidson, D.L. Schriger, B. Lorber, W.H. Herman.
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Diabetes Care, 26 (2003), pp. 1796-1801
[7.]
D.E. Kelley, J.A. Simoneau.
Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus.
J Clin Invest, 94 (1994), pp. 2349-2356
[8.]
A.D. Sniderman, T. Scantlebury, K. Cianflone.
Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus.
Ann Intern Med, 135 (2001), pp. 447-459
[9.]
S. Rashid, P.H. Barrett, K.D. Uffelman, T. Watanabe, K. Adeli, G.F. Lewis.
Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation.
Arterioscler Thromb Vasc Biol, 22 (2002), pp. 483-487
[10.]
K.C. Tan, M.B. Cooper, K.L. Ling, B.A. Griffin, D.J. Freeman, C.J. Packard, et al.
Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance.
Atherosclerosis, 113 (1995), pp. 273-287
[11.]
M.A. Austin, M.C. King, K.M. Vranizian, R.M. Krauss.
Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk.
Circulation, 82 (1990), pp. 495-506
[12.]
B. Lamarche, A. Tchernof, S. Moorjani, B. Cantin, G.R. Dagenais, P.J. Lupien, et al.
Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. prospective results from the quebec cardiovascular study.
Circulation, 95 (1997), pp. 69-75
[13.]
R. Ross.
Atherosclerosis: an inflammatory disease.
N Engl J Med, 340 (1999), pp. 115-126
[14.]
P.C. Choy, Y.L. Siow, D. Mymin.
Lipids and atherosclerosi.
Biochem Cell Biol, 82 (2004), pp. 212-224
[15.]
K. Winkler, C. Ablestshauser, M.M. Hoffmann, I. Friedrich, M.W. Baumstark, H. Wieland, et al.
Effect of fluvastatin slow release on Low Density Lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.
J Clin Endocrinol Metab, 87 (2002), pp. 5485-5490
[16.]
C.M. Ballantyne, F. Pazzucconi, X. Pinto, J.P. Reckless, E. Stein, J. McKenney, et al.
Efficacy and tolerability of fluvastatin extendedrelease delivery system: a pooled analysis.
Clin Ther, 23 (2001), pp. 177-192
[17.]
S.J. Bredie, T.W. De Bruin, P.N. Demacker, J.J. Kastelein, A.F. Stalenhoef.
Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and lowdensity lipoprotein oxidizability.
Am J Cardiol, 75 (1999), pp. 348-353
[18.]
S.M. Haffner, C.M. Alexander, T.J. Cook, S.J. Boccuzzi, T.A. Musliner, T.R. Pedersen, et al.
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the scandinavian simvastatin survival study.
Arch Intern Med, 159 (1999), pp. 2661-2667
[19.]
M. Brandle, M.B. Davidson, D.L. Schriger, B. Lorber, W.H. Herman.
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Diabetes Care, 26 (2003), pp. 1796-1801
[20.]
Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[21.]
R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto.
Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial.
Lancet, 361 (2003), pp. 2005-2016
[22.]
P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al.
ASCOT investigators. prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT- LLA): a multicentre randomised controlled trial.
Lancet, 361 (2003), pp. 1149-1158
[23.]
H.M. Colhoun, M.J. Thomason, M.I. Mackness, et al.
Collaborative AtoRvastatin Diabetes Study(CARDS). design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
Diabet Med, 19 (2002), pp. 201-211
[24.]
C.J. Pepine, R.E. Heining.
Managing lipids in patients with diabetes: new evidence from vascular biology and clinical trials.
Vascular Biology in Clinical Practice, 5 (2003), pp. 1-6
[25.]
V. Snow, M.D. Aronson, E.R. Horbake, C. Mottur-Pilson, K.B. Weiss.
Clinical efficacy assessment subcommittee of the american college of physicians lipid control in the management of type 2 diabetes mellitus a clinical practice guideline from the american college of physicians.
Ann Intern Med, 140 (2004), pp. 644-649
[26.]
R.S. Rosenson, C. Tangney.
Antiatherothrombotic properties of statins.
JAMA, 279 (1998), pp. 1643-1650
[27.]
S. Bellosta, N. Ferri, L. Arnaboldi, F. Bernini, R. Paoletti, A. Corsini.
Pleiotropic effects of statins in atherosclerosis and diabetes.
Diabetes Care, 23 (2000), pp. B72-8
[28.]
J.A. Herd, C.M. Ballantyne, J.A. Farmer, J.J. Ferguson, P.H. Jones, M.S. West, et al.
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS].
Am J Cardiol, 80 (1997), pp. 278-286
[29.]
P.W. Serruys, P. De Feyter, C. Macaya, N. Kokott, J. Puel, M. Vrolix, et al.
Lescol Intervention Prevention Study (LIPS) investigators. fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.
JAMA, 287 (2002), pp. 3215-3222
[30.]
A.M. Kanaya, B. Grady, E. Barrett-Connor.
Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus.
Arch Int Med, 162 (2002), pp. 1737-1745
[31.]
S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[33.]
R. Holman.
The UKPDS: implications for the dyslipidaemic patient.
Acta Diabetol, 38 (2001), pp. S9-S14
[34.]
H.B Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, et al.
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. veterans affairshigh-density lipoprotein cholesterol intervention trial study group.
N Engl J Med, 341 (1999), pp. 410-830
[35.]
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes diabetes atherosclerosis intervention study.
Lancet, 357 (2001), pp. 905-910
[36.]
P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, O. Pedersen.
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med, 348 (2003), pp. 383-393
[37.]
S.M. Grundy, I.J. Benjamin, G.l. Burke, et al.
Diabetes and cardiovascular disease. a statement for healthcare professionals from the american heart association.
Circulation, 100 (1999), pp. 1134-1146
[38.]
A.O. Marcus.
Lipid disorders in patients with type 2 diabetes. meeting the challenges of a early aggressive treatment.
Postgrad Med, 110 (2001), pp. 111-123
[39.]
J.D. Brunzell, A.F. Ayyobi.
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Am J Med, 115 (2003), pp. S24-8
[40.]
G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, et al.
Third joint force of european and other societies on cardiovascular disease and prevention in clinical practice. european guidelines on cardiovascular disease and prevention in clinical practice.
Atherosclerosis, 171 (2003), pp. 145-155
[41.]
J.M. Evans, J. Wang, A.D. Morris.
Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies.
BMJ, 324 (2002), pp. 939-942
[42.]
H.D. Juan, H. Bueno.
¿Tiene el paciente con diabetes tipo 2 un riesgo equivalente al del paciente con enfermedad coronaria establecida?.
Endocrinol Nutr, 50 (2003), pp. 3-7
[43.]
M. Farnier, T. Salko, J.L. Isaacsohn, A.J. Troendle, S. Dejager, L. Gonasun.
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil.
Am J Cardiol, 92 (2003), pp. 794-797
[44.]
C. Scripture, J.A. Pieper.
Clinical pharmacokinetics of fluvastatin.
Clin Pharmacokinet, 40 (2001), pp. 263-281
[45.]
S.M. Grundy, G.L. Vega, M.E. McGovern, B.R. Tulloch, D.M. Kendall, D. Fitz-Patrick, et al.
Diabetes multicenter research group. efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Arch Intern Med, 162 (2002), pp. 1568-1576
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.